Perillyl alcohol is an angiogenesis inhibitor

Loutrari, H; Hatziapostolou, M; Skouridou, V; Papadimitriou, E; Roussos, C; Kolisis, FN; Papapetropoulos, A

dc.contributor.author	Loutrari, H	en
dc.contributor.author	Hatziapostolou, M	en
dc.contributor.author	Skouridou, V	en
dc.contributor.author	Papadimitriou, E	en
dc.contributor.author	Roussos, C	en
dc.contributor.author	Kolisis, FN	en
dc.contributor.author	Papapetropoulos, A	en
dc.date.accessioned	2014-03-01T01:21:13Z
dc.date.available	2014-03-01T01:21:13Z
dc.date.issued	2004	en
dc.identifier.issn	0022-3565	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/16138
dc.subject.classification	Pharmacology & Pharmacy	en
dc.subject.other	angiogenesis inhibitor	en
dc.subject.other	angiopoietin 2	en
dc.subject.other	caspase 3	en
dc.subject.other	collagen gel	en
dc.subject.other	DNA fragment	en
dc.subject.other	matrigel	en
dc.subject.other	perillyl alcohol	en
dc.subject.other	protein kinase B	en
dc.subject.other	terpene derivative	en
dc.subject.other	vasculotropin	en
dc.subject.other	angiogenesis	en
dc.subject.other	animal cell	en
dc.subject.other	antineoplastic activity	en
dc.subject.other	apoptosis	en
dc.subject.other	article	en
dc.subject.other	blood vessel	en
dc.subject.other	cancer prevention	en
dc.subject.other	cell count	en
dc.subject.other	cell differentiation	en
dc.subject.other	cell growth	en
dc.subject.other	cell proliferation	en
dc.subject.other	cell survival	en
dc.subject.other	chemoprophylaxis	en
dc.subject.other	chick embryo	en
dc.subject.other	chorioallantois	en
dc.subject.other	controlled study	en
dc.subject.other	drug efficacy	en
dc.subject.other	endothelium cell	en
dc.subject.other	enzyme activity	en
dc.subject.other	hematologic malignancy	en
dc.subject.other	in vivo study	en
dc.subject.other	inhibition kinetics	en
dc.subject.other	neovascularization (pathology)	en
dc.subject.other	nonhuman	en
dc.subject.other	priority journal	en
dc.subject.other	protein phosphorylation	en
dc.subject.other	solid tumor	en
dc.subject.other	Angiogenesis Inhibitors	en
dc.subject.other	Angiopoietin-2	en
dc.subject.other	Animals	en
dc.subject.other	Cattle	en
dc.subject.other	Cell Count	en
dc.subject.other	Cell Survival	en
dc.subject.other	Cells, Cultured	en
dc.subject.other	Endothelium, Vascular	en
dc.subject.other	Gene Expression	en
dc.subject.other	Monoterpenes	en
dc.subject.other	Neovascularization, Physiologic	en
dc.subject.other	Protein-Serine-Threonine Kinases	en
dc.subject.other	Proto-Oncogene Proteins	en
dc.subject.other	Proto-Oncogene Proteins c-akt	en
dc.subject.other	Vascular Endothelial Growth Factor A	en
dc.title	Perillyl alcohol is an angiogenesis inhibitor	en
heal.type	journalArticle	en
heal.identifier.primary	10.1124/jpet.104.070516	en
heal.identifier.secondary	http://dx.doi.org/10.1124/jpet.104.070516	en
heal.language	English	en
heal.publicationDate	2004	en
heal.abstract	Aberrant angiogenesis is essential for the progression of solid tumors and hematological malignancies. Thus, antiangiogenic therapy is one of the most promising approaches to control cancer. In the present work, we examined the ability of perillyl alcohol (POH), a dietary monoterpene with well-established tumor chemopreventive and chemotherapeutic activity, to interfere with the process of angiogenesis. POH remarkably prevented new blood vessel growth in the in vivo chicken embryo chorioallantoic membrane assay and proved to be effective in inhibiting the morphogenic differentiation of cultured endothelial cells into capillary-like networks both in collagen gel and Matrigel models. In addition, POH reduced the cell number in a proliferation assay and induced apoptosis of endothelial cells as indicated by the POH-mediated increase of caspase-3 activity and DNA fragmentation. Consistent with the observed antisurvival effect, POH treatment resulted in a significant inhibition of Akt phosphorylation in endothelial cells. Finally, POH was able to differentially modulate the release of two important angiogenic regulators: vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2). POH decreased the release of VEGF from cancer cells but stimulated the expression of Ang2 by endothelial cells, indicating that it might suppress neovascularization and induce vessel regression. Overall, these data underscore the antiangiogenic potential of POH and suggest that POH, in addition to its anticancer activity, may be an effective agent in the treatment of angiogenesis-dependent diseases.	en
heal.publisher	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	en
heal.journalName	Journal of Pharmacology and Experimental Therapeutics	en
dc.identifier.doi	10.1124/jpet.104.070516	en
dc.identifier.isi	ISI:000224456400016	en
dc.identifier.volume	311	en
dc.identifier.issue	2	en
dc.identifier.spage	568	en
dc.identifier.epage	575	en